EDC for Phase 1 Clinical Trials

Electronic data capture built for Phase 1 trials: protocol flexibility, safety reporting, and 21 CFR Part 11–aligned controls without enterprise overhead.

21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required

Example Phase 1 designs you can support

Common Phase 1 designs include single-ascending-dose (SAD), multiple-ascending-dose (MAD), food-effect, and bioavailability studies. Each design follows a similar pattern—screening, dosing, intensive PK and safety follow-up—but differs in the number of cohorts, sampling schedules, and review points. Capture lets you configure each of these patterns once and then reuse them across related protocols, so your team is not rebuilding CRFs and visit schedules every time you launch a new early-phase study.

  • Single-ascending-dose cohorts with sentinel dosing and intensive post-dose safety checks
  • Multiple-ascending-dose cohorts with steady-state sampling and safety labs over several days or weeks
  • Food-effect studies with crossover designs and timing-sensitive PK draws
  • Bioavailability or bioequivalence studies with dense PK sampling and standardized safety panels

What Phase 1 monitors and inspectors expect to see

Monitors and inspectors focus on traceability: they want a clear link from protocol and consent through dosing decisions, safety assessments, and data exports. In practice this means consistent CRF layouts, clear audit trails for any mid-study changes, and the ability to reconstruct exactly what happened at a given time point. Capture helps by keeping consent, CRFs, and AEs in one system with detailed audit history and role-based access, so your team can respond quickly to questions during monitoring visits or inspections.

  • Clearly versioned consent records tied to individual participants and visits
  • Audit trails that show who changed what, when, and why for forms and visits
  • Consistent capture of AEs, conmeds, and protocol deviations with follow-up status
  • Exports that align with your analysis and reporting plan so listings are easy to review

How Phase 1 workflows map onto Capture.Study

In Capture, Phase 1 workflows are implemented using the same building blocks described elsewhere on the site: eConsent for informed consent, CRFs for PK, safety and lab data, ePRO when you need participant-reported measures, and configurable visit schedules and roles. The goal is to keep everything visible in one place so coordinators, investigators, data managers and monitors can rely on a shared view of the study, while still aligning with your existing validation and governance processes.

  • Use eConsent to manage versioned ICFs and electronic signatures for each participant
  • Configure visit schedules and CRFs to reflect your SAD, MAD or food-effect protocol design
  • Enable ePRO only when the protocol calls for participant-reported outcomes; otherwise keep the stack lean
  • Give monitors read-only access with dashboards and queries that match how they already review data

Overview

EDC for Phase 1 Clinical Trials

Phase 1 clinical trials focus on safety, tolerability, and pharmacokinetics in a small number of healthy volunteers or patients. These studies generate dense safety and PK/PD data, require frequent protocol amendments as early data emerges, and need to move quickly from protocol approval to first subject in. Designs often include single-ascending-dose (SAD), multiple-ascending-dose (MAD), and food-effect cohorts, each with its own schedule of assessments, sampling windows, and safety follow-up. That translates into a lot of structured data: vital signs and ECGs at specific time points, serial PK samples, repeated safety labs, and careful documentation of adverse events and concomitant medications. Your EDC must support rapid build and go-live, flexible visit and form design for complex sampling schedules, adverse event capture with proper follow-up, and full auditability—without the cost and complexity of systems built for large Phase 3 programs. It also has to be understandable for lean site teams who may be using a modern EDC for the first time, while still providing the audit trails and access controls that monitors, QA, and inspectors expect. When you add in the realities of limited internal IT support and tight development timelines, Phase 1 teams benefit from an EDC that emphasizes configuration over custom development and can be reused as a blueprint across multiple early-phase protocols.

Why Phase 1 is different

Phase 1 studies often have smaller teams, tighter timelines, and protocols that change as early data comes in. You need an electronic data capture system that can be configured quickly, supports safety and lab workflows, and maintains audit trails and access controls suitable for regulatory scrutiny. Unlike Phase 3, you typically don’t need hundreds of sites or complex global supply chains—you need agility, clear audit trails for inspectors, and the ability to amend visits and forms without months of change control. Sponsors and CROs running Phase 1 also need cost-effective tools that scale with cohort size rather than enterprise licensing models. In practice that means being able to add or adjust PK sampling time points, change visit windows, or refine safety follow-up forms without triggering long vendor projects. It also means having a system that can support different flavors of Phase 1 (SAD, MAD, bioavailability, food-effect) without designing everything from scratch each time.

Common Phase 1 workflow

  • Protocol finalization and frequent amendments as PK/safety data informs design
  • Site selection and activation (often one or a few sites)
  • Screening, consent, and enrollment with eligibility checks
  • Dense PK/PD and safety data collection at defined time points
  • Adverse event capture, severity, causality, and follow-up reporting
  • Concomitant medication and protocol deviation tracking
  • Ongoing monitoring, data review, and query resolution with site staff and monitors
  • Interim safety reviews and potential protocol adjustments based on emerging data
  • Preparation of listings and exports for safety review meetings and pharmacokinetic analyses
  • Database lock and export for pharmacokinetic and safety analysis

Traditional tool pain points

  • Long implementation cycles that delay first-patient-in and extend study timelines
  • Heavy validation and change-control processes for simple protocol tweaks and form updates
  • Per-seat or per-module pricing that doesn’t scale with small cohorts and burns budget
  • Systems built for large Phase 3 studies, with features and complexity you don’t need
  • Separate tools for EDC, eConsent, and ePRO that don’t share one audit trail or one build
  • Slow vendor support for study build and amendments when timelines are tight
  • Limited flexibility to model dense sampling schedules or non-standard visit structures common in Phase 1
  • Difficulty reusing successful Phase 1 designs as blueprints across related compounds or indications

How Capture supports Phase 1

  • Unified EDC with eConsent, ePRO, and case report forms in one platform so sites and sponsors use one system
  • Rapid study build and amendment support so you can adapt visits, forms, and logic without lengthy change control
  • Built-in safety and AE workflows with severity, causality, follow-up, and full audit trails and role-based access
  • Flexible CRF design for PK/PD sampling schedules, repeated measures, and time-point–based collection
  • 21 CFR Part 11–aligned controls: electronic signatures, comprehensive audit trails, and access controls
  • HIPAA-aligned security and data handling for participant data and PHI
  • Export for analysis and regulatory submissions when you’re ready to lock; documentation to support sponsor validation (Enterprise)
  • Configurable roles and permissions so laboratory staff, investigators, and monitors see the right views without extra complexity
  • Ability to clone and adapt existing Phase 1 studies so you can standardize core designs while tailoring details to each protocol

Related

Clinical trial softwareAffordable EDC for clinical trialsEDC with built-in ePRO

FAQ

Questions we hear a lot

Is Capture suitable for Phase 1 trials?
Yes. Capture is designed for early-phase and small-to-mid-size trials. You get EDC, eConsent, ePRO, and safety workflows in one platform, with 21 CFR Part 11–aligned controls and audit trails. Many teams use Capture for Phase 1 and Phase 2 studies where speed and flexibility matter. For regulated studies, we provide documentation and support for qualification and UAT as part of Enterprise offerings.
How do you handle protocol amendments?
You can update forms, visits, and logic in the study build. Changes are tracked in the audit trail so you have a clear record for regulatory review. For substantial amendments, we recommend documenting the change and, for regulated studies, following your validation and change-control procedures. Capture is designed to support iterative protocol updates without long vendor lead times.
Can we capture PK/PD and safety data?
Yes. Capture supports custom case report forms, repeated measures, and time-point–based data collection so you can model dense PK and safety sampling. Adverse events can be captured with severity, causality, and follow-up. All data is stored with full audit history and can be exported for pharmacokinetic and safety analysis.
What about regulatory compliance?
Capture is designed with 21 CFR Part 11–aligned controls: electronic signatures, comprehensive audit trails, and role-based access. Infrastructure is HIPAA-aligned for participant data. We do not make unsubstantiated “validated” claims; for sponsor validation we provide documentation and support for qualification and UAT as part of Enterprise offerings.
How quickly can we go live for a Phase 1 study?
Study build can start as soon as you have protocol and CRF requirements. Many teams build and deploy Phase 1 studies in weeks rather than months. For regulated studies, onboarding may include validation, documentation, and sponsor-led UAT prior to go-live—we support that process with the documentation you need.
Can we reuse our Phase 1 build for later studies?
Yes. Many teams treat a well-designed Phase 1 study as a blueprint for similar early-phase protocols. You can clone studies, adjust visits and forms, and maintain a consistent approach to consent, safety, and PK capture while still documenting changes in the audit trail.
Where is Capture hosted and how is data secured?
Capture is hosted in cloud infrastructure with HIPAA-aligned security controls. Access is managed via role-based permissions, and all data access is tracked in audit logs. We can share more detail as part of a security and compliance review under NDA.
Can sites work from standard browsers without installing software?
Yes. Capture is delivered as a web application, so investigators, coordinators, and monitors can access studies via modern browsers without installing thick clients. This matches what you see on the public Capture.Study site and demo environment.
Does Capture support both healthy volunteer and patient Phase 1 designs?
Yes. You can configure CRFs, cohorts, and visits to match healthy volunteer or patient-based designs. The underlying platform—EDC, eConsent, ePRO, and safety—remains the same; you tailor forms and schedules to your specific protocol.
How does Capture fit into our existing validation process?
Capture is designed with 21 CFR Part 11–aligned controls and HIPAA-aligned security. Sponsors remain responsible for validating their use of the system. For Enterprise implementations we provide documentation and support for qualification and user acceptance testing so you can fit Capture into your existing validation framework.

Ready to see Capture in action?

Explore the platform with a free sandbox. No sales call required.